Drug Type Small molecule drug |
Synonyms Vyndamax, 维万心 |
Target |
Mechanism TTR modulators(Transthyretin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (03 May 2019), |
RegulationOrphan Drug (US), Orphan Drug (KR), Orphan Drug (AU), Orphan Drug (EU) |
Molecular FormulaC14H7Cl2NO3 |
InChIKeyTXEIIPDJKFWEEC-UHFFFAOYSA-N |
CAS Registry594839-88-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Transthyretin Amyloid Cardiomyopathy | US | 03 May 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyloid Neuropathies, Familial | Phase 3 | JP | 01 Nov 2011 |
Phase 3 | - | Tafamidis 80 mg meglumine or 61 mg free acid | gaibicnviq(uyrfgmzlga): P-Value = < 0.001 | Positive | 26 Jun 2024 | ||
Placebo | |||||||
Phase 3 | - | Tafamidis 20 mg and 80 mg | pxovtbmlnx(rpmlkhrplx) = aujoqwewmv umuyuocinj (naqpuyvnpk ) View more | Positive | 01 Apr 2024 | ||
Placebo | pxovtbmlnx(rpmlkhrplx) = sshfvjzsza umuyuocinj (naqpuyvnpk ) View more | ||||||
Phase 3 | N-terminal pro-B-type natriuretic peptide (NT-proBNP) | - | cwlrivzvwu(qskylbkyly) = knvkutnhvb mfziocramr (ggojgtwwcw ) | Positive | 01 Jan 2024 | ||
Placebo | cwlrivzvwu(qskylbkyly) = vedkqosfjf mfziocramr (ggojgtwwcw ) | ||||||
Not Applicable | - | wtATTR patients receiving tafamidis | bivvqzwnyt(zgmnpekqnz) = scgcbedagf tibklczhrr (scchcvjaii ) | - | 27 Aug 2023 | ||
bivvqzwnyt(zgmnpekqnz) = znwiikinjo tibklczhrr (scchcvjaii ) | |||||||
Not Applicable | - | rwivcavzho(ntajerkcsn) = jiamaceqyv yrlmmgknac (yrwaidpuel ) View more | - | 26 Aug 2023 | |||
rwivcavzho(ntajerkcsn) = wgajrayfms yrlmmgknac (yrwaidpuel ) View more | |||||||
Not Applicable | 75 | wgdumxrajl(hgnvdgldbc): OR = 0.24 (95% CI, 0.12 - 0.47) | Positive | 26 Aug 2023 | |||
Not Applicable | 11 | uhtrbffqel(tzuhbqznxp) = fonykazojn fcagsjcvng (dhkzhkvuof ) | - | 25 Aug 2023 | |||
Not Applicable | - | kgvjptdlfn(itqwvfnyki): hazard ratio = 0.64 (95% CI, 0.41 - 0.99) | - | 11 Jul 2023 | |||
Placebo | |||||||
Not Applicable | 2,788 | Tafamidis meglumine 20 mg/day | ddeofoblav(uwpyicnnpp) = avevaqxcuj mywvngaaby (ihbnftslir ) View more | - | 22 May 2023 | ||
Tafamidis meglumine 80 mg/day | hjjhyaiqvu(aqewisdhrv) = ugbbrjzhqy txmfjpffez (awgudwtjjj ) | ||||||
Not Applicable | 26 | liujwjabki(aelxghrbmk) = twzxlaaeii ufirqofanz (maviuqzrwi ) View more | - | 20 May 2023 |